Rajeev Saggar
Chief Tech/Sci/R&D Officer chez LIQUIDIA CORPORATION
Fortune : 3 M $ au 31/03/2024
Profil
Rajeev Saggar is currently the Chief Medical Officer at Liquidia Corp.
Prior to this, he was the Vice President of Clinical Development at Theravance Biopharma US, Inc. from 2021 to 2022.
He also served as the Medical Director for Pulmonary Hypertension & Fibrosis at The Banner-University Medical Center.
Dr. Saggar holds a doctorate degree from the University of California, Irvine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LIQUIDIA CORPORATION
0,28% | 19/04/2024 | 211 672 ( 0,28% ) | 3 M $ | 31/03/2024 |
Postes actifs de Rajeev Saggar
| Sociétés | Poste | Début |
|---|---|---|
| LIQUIDIA CORPORATION | Chief Tech/Sci/R&D Officer | 18/07/2022 |
Anciens postes connus de Rajeev Saggar
| Sociétés | Poste | Fin |
|---|---|---|
Theravance Biopharma US, Inc.
 Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/07/2022 |
| The Banner-University Medical Center | Corporate Officer/Principal | - |
Formation de Rajeev Saggar
| University of California, Irvine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LIQUIDIA CORPORATION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Theravance Biopharma US, Inc.
Theravance Biopharma US, Inc. Miscellaneous Commercial ServicesCommercial Services Theravance Biopharma US, Inc. operates as a biopharmaceutical company. The firm serves in the areas of inflammation and immunology, drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol. The company is headquartered in South San Francisco, CA. | Commercial Services |
